165 related articles for article (PubMed ID: 21555002)
1. EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.
Pradhan AK; Kuila N; Singh S; Chakraborty S
Biochim Biophys Acta; 2011; 1809(4-6):269-75. PubMed ID: 21555002
[TBL] [Abstract][Full Text] [Related]
2. SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
Singh S; Pradhan AK; Chakraborty S
Biochim Biophys Acta; 2013 Oct; 1833(10):2357-68. PubMed ID: 23770046
[TBL] [Abstract][Full Text] [Related]
3. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
5. EVI1 targets ΔNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells.
Nayak KB; Kuila N; Das Mohapatra A; Panda AK; Chakraborty S
Int J Biochem Cell Biol; 2013 Aug; 45(8):1568-76. PubMed ID: 23665236
[TBL] [Abstract][Full Text] [Related]
6. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.
Spensberger D; Vermeulen M; Le Guezennec X; Beekman R; van Hoven A; Bindels E; Stunnenberg H; Delwel R
Biochemistry; 2008 Jun; 47(24):6418-26. PubMed ID: 18500823
[TBL] [Abstract][Full Text] [Related]
7. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.
Senyuk V; Zhang Y; Liu Y; Ming M; Premanand K; Zhou L; Chen P; Chen J; Rowley JD; Nucifora G; Qian Z
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5594-9. PubMed ID: 23509296
[TBL] [Abstract][Full Text] [Related]
8. Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis.
Pradhan AK; Mohapatra AD; Nayak KB; Chakraborty S
PLoS One; 2011; 6(9):e25370. PubMed ID: 21980434
[TBL] [Abstract][Full Text] [Related]
9. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
10. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
[TBL] [Abstract][Full Text] [Related]
11. [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
Fuchs O
Cas Lek Cesk; 2006; 145(8):619-24. PubMed ID: 16995417
[TBL] [Abstract][Full Text] [Related]
12. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
13. Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response.
Bingemann SC; Konrad TA; Wieser R
FEBS J; 2009 Nov; 276(22):6810-22. PubMed ID: 19843176
[TBL] [Abstract][Full Text] [Related]
14. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
[TBL] [Abstract][Full Text] [Related]
15. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.
Spensberger D; Delwel R
FEBS Lett; 2008 Aug; 582(18):2761-7. PubMed ID: 18619962
[TBL] [Abstract][Full Text] [Related]
16. EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity.
Chi Y; Senyuk V; Chakraborty S; Nucifora G
J Biol Chem; 2003 Dec; 278(50):49806-11. PubMed ID: 14555651
[TBL] [Abstract][Full Text] [Related]
17. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
18. Set7/9 impacts COL2A1 expression through binding and repression of SirT1 histone deacetylation.
Oppenheimer H; Kumar A; Meir H; Schwartz I; Zini A; Haze A; Kandel L; Mattan Y; Liebergall M; Dvir-Ginzberg M
J Bone Miner Res; 2014 Feb; 29(2):348-60. PubMed ID: 23873758
[TBL] [Abstract][Full Text] [Related]
19. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
[TBL] [Abstract][Full Text] [Related]
20. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
